PharmaRoth Looks Abroad With Type 2 Diabetes Product After NDI Notification Decision
This article was originally published in The Tan Sheet
Executive Summary
FDA decides Sucanon is an investigational new drug, not a dietary ingredient, in response to PharmaRoth Labs’ NDI notification. The firm expected to sell Sucanon as a consumer health supplement via infomercials with no claims, but faces substantially higher costs on the IND pathway to market.
You may also be interested in...
AstraZeneca’s Farxiga Label Includes, But Downplays, Bladder Cancer Risk
AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) finally clears FDA, and without a black box warning on bladder cancer risk – allowing the drug to compete with J&J’s first-to-market Invokana.
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
Large outcomes studies showed neither cardiovascular harm nor benefit with BMS/AstraZeneca’s saxagliptin or Takeda’s alogliptin, prompting some commenters to question whether FDA’s blanket approach to CV safety for all antidiabetic agents needs adjustment.
Avandia Panel Wants Another Trial: Pipe Dream Or Post-market Benchmark?
Designed with complex, multi-variate statistics, an observational trial could determine the CV risk of rosiglitazone compared to other diabetes drugs, an advisory committee member suggests during the latest assessment of Avandia.